key: cord-0854715-p17z8yeb
authors: Schmidt, A.L.; Labaki, C.; Hsu, C.-Y.; Bakouny, Z.; Balanchivadze, N.; Berg, S.A.; Blau, S.; Daher, A.; El Zarif, T.; Friese, C.R.; Griffiths, E.A.; Hawley, J.E.; Hayes-Lattin, B.; Karivedu, V.; Latif, T.; Mavromatis, B.H.; McKay, R.R.; Nagaraj, G.; Nguyen, R.H.; Panagiotou, O.A.; Portuguese, A.J.; Puc, M.; Dutra, M. Santos; Schroeder, B.A.; Thakkar, A.; Wulff-Burchfield, E.M.; Mishra, S.; Farmakiotis, D.; Shyr, Yu; Warner, J.L.; Choueiri, T.K.
title: COVID-19 Vaccination and Breakthrough Infections in Patients with Cancer
date: 2021-12-24
journal: Ann Oncol
DOI: 10.1016/j.annonc.2021.12.006
sha: a05a5aca764857de71a5a983923bdfb7c85082f3
doc_id: 854715
cord_uid: p17z8yeb

BACKGROUND: Vaccination is an important preventive health measure to protect against symptomatic and severe COVID-19. Impaired immunity secondary to an underlying malignancy or recent receipt of anti-neoplastic systemic therapies can result in less robust antibody titres following vaccination and possible risk of breakthrough infection. As clinical trials evaluating COVID-19 vaccines largely excluded patients with a history of cancer and those on active immunosuppression (including chemotherapy), limited evidence is available to inform the clinical efficacy of COVID-19 vaccination across the spectrum of patients with cancer. PATIENTS AND METHODS: We describe the clinical features of patients with cancer who developed symptomatic COVID-19 following vaccination and compare weighted outcomes to those of contemporary unvaccinated patients, after adjustment for confounders, using data from the multi-institutional COVID-19 and Cancer Consortium (CCC19; ClinicalTrials.gov number, NCT04354701). RESULTS: Patients with cancer who develop COVID-19 following vaccination have substantial comorbidities and can present with severe and even lethal infection. Patients harboring hematologic malignancies are over-represented among vaccinated patients with cancer who develop symptomatic COVID-19. CONCLUSIONS: Vaccination against COVID-19 remains an essential strategy in protecting vulnerable populations, including patients with cancer. However, patients with cancer who develop breakthrough infection despite full vaccination remain at risk of severe outcomes. A multilayered public health mitigation approach that includes vaccination of close contacts, boosters, social distancing, and mask-wearing should be continued for the foreseeable future.

Vaccination is an important preventive health measure to protect against symptomatic and severe COVID-19. Impaired immunity secondary to an underlying malignancy or recent receipt of anti-neoplastic systemic therapies can result in less robust antibody titres following vaccination and possible risk of breakthrough infection. As clinical trials evaluating COVID-19 vaccines largely excluded patients with a history of cancer and those on active immunosuppression (including chemotherapy), limited evidence is available to inform the clinical efficacy of COVID-19 vaccination across the spectrum of patients with cancer.

We describe the clinical features of patients with cancer who developed symptomatic COVID-19 following vaccination and compare weighted outcomes to those of contemporary unvaccinated patients, after adjustment for confounders, using data from the multiinstitutional COVID-19 and Cancer Consortium (CCC19; ClinicalTrials.gov number, NCT04354701).

Patients with cancer who develop COVID-19 following vaccination have substantial comorbidities and can present with severe and even lethal infection. Patients harboring hematologic malignancies are over-represented among vaccinated patients with cancer who develop symptomatic COVID-19.

Vaccination against COVID-19 remains an essential strategy in protecting vulnerable populations, including patients with cancer. However, patients with cancer who develop breakthrough infection despite full vaccination remain at risk of severe outcomes. A

The development of effective vaccines against COVID-19, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has allowed widespread vaccination programs aimed at reducing symptomatic and severe 2 The presence of underlying immunosuppression and receipt of recent systemic therapy for cancer have been associated with prolonged or severe infection and may reduce the efficacy of vaccination. [3] [4] [5] [6] [7] [8] Lower seroconversion rates following the receipt of COVID-19 vaccines have been observed in patients with underlying malignancy compared to non-cancer controls, with more concerning findings seen in patients with hematologic malignancies compared to those with solid cancers. 7, 9 The clinical impact of these serological alterations is yet to be evaluated and the characteristics of breakthrough COVID-19 in vaccinated patients with cancer have not been reported, potentially due to low prevalence of SARS-CoV-2 during the time period of the published reports. Clinical trials evaluating COVID-19 vaccines report a high efficacy in the general population, with few-to-no severe breakthrough infections. 1, 2 As patients with a history of cancer and those on active immunosuppression (including chemotherapy) were largely excluded from these landmark studies, scant evidence informs the clinical efficacy of COVID-19 vaccination across the spectrum of patients with cancer. Given the predisposition of patients with cancer to suffer from severe outcomes in SARS-CoV-2 infection 10 and considering their potential susceptibility to mount a less effective immune response following vaccination 11 , better characterization of breakthrough COVID-19 following vaccination in this vulnerable population is needed.

Here, we sought to report the clinical attributes of patients with cancer who develop breakthrough SARS-CoV-2 infections and compare their weighted outcomes with those seen J o u r n a l P r e -p r o o f in a contemporary unvaccinated population, using data from the multi-institutional COVID- 19 and Cancer Consortium (CCC19) registry.

The large international CCC19 registry captures data on patients with a current or prior history of cancer who develop COVID-19 through a REDCap survey with methodology outlined previously. 10, 12 Deidentified data are collected using a comprehensive set of variables related to demographics, cancer status, anti-cancer therapies, SARS-CoV-2 infection, and COVID-19 vaccination. Data on COVID-19 vaccination was routinely collected on every newly entered case beginning with the first global approval in November 2020. Eligible cases included adult patients (>18 years) accrued from 1 November 2020 to 31 May 2021 with current or prior history of invasive cancer and laboratory-confirmed SARS-CoV-2 infection. Patients were excluded if vaccination status or timing was unknown or if the vaccine was administered after SARS-CoV-2 infection. We also excluded cases with poor data quality (score 5 or higher using the previously defined metric). 13 The primary endpoint was 30-day all-cause mortality among fully vaccinated patients compared to the unvaccinated population after Inverse Probability of Treatment Weighting The data dictionary used in the analysis, along with instructions on how to access to full CCC19 data dictionary and code to generate derived variables is found in Supplementary Among the 54 fully vaccinated patients who developed COVID-19, 35 (65%) were hospitalized, 10 (19%) were admitted to ICU or required MV, and 7 (13%) died within 30 days. Comparable rates were observed in the unvaccinated group (Table 1) .

Following IPTW (Table 2 

There were no significant differences in ICU/MV or hospitalization rates between the vaccinated patients compared to the unvaccinated cohort after adjustment (AOR 1·13, 95% CI: 0·54-2·37 and AOR 1·25, 95% CI: 0·68-2·30, respectively). In both vaccinated and unvaccinated patients higher ICU/MV and hospitalization rates were identified in patients with lymphopenia (AOR 1·43, 95% CI: 1·03-1·97 and AOR 1·62, 95% CI: 1·20-2·20, respectively), the presence of comorbid conditions (mCCI of ≥2 vs 0: AOR 2·19, 95% CI:

1·32-3·64 and mCCI 1 vs 0: AOR: 2·42, 95% CI: 1·71-3·43), poor ECOG PS (ECOG PS ≥2 vs 0: AOR 2·19, 95% CI: 1·32-3·64 and ECOG PS 1 vs 0: AOR 3·68, 95% CI: 2·46-5·53) and hematologic, as opposed to solid cancers (AOR 2·00, 95% CI: 1·41-2·83, and AOR 2·42, 95% CI: 1·82-3·22, respectively).

To our knowledge, this is the first study to evaluate the clinical characteristics and outcomes of patients with cancer who experience breakthrough infection following COVID-19

vaccination. Vaccination has been widely effective at reducing the severity of SARS-CoV-2 infection, but the protection afforded by this preventive modality can be incomplete, and despite the high efficacy rates identified in clinical trials, 1,2 some patients (such as the ones with cancer) remain at risk of developing symptomatic COVID-19, with potentially severe adverse outcomes. Vaccine effectiveness has been studied extensively in the general population as well as in patients with cancer and appears to wane over time. Based on the accumulation of knowledge to date, it appears that patients with hematologic malignancy are less likely to mount an effective immune response. 16 The enrichment of hematologic malignancies (35% versus 20%) in this cohort is consistent with evidence that these patients may have a blunted serologic response to vaccination secondary to disease or therapy, 17, 18 compounding their probability to develop more severe COVID-19 outcomes relative to patients with other types of tumors. 19 

The described vaccinated cohort may be subject to ascertainment bias as a result of selective reporting, if reporting sites did not attain complete coverage of all eligible cases. were not yet available during the timeframe of this study, and are not part of the definitions of fully vaccinated used in the original trials, which we adopted. 2, 14, 1 The mortality and ICU/MV rates of 13% and 19%, respectively, recorded in the fully vaccinated group, with no significant differences compared to the unvaccinated group, represent a considerable residual risk. Additionally, this contrasts with a substantially lower rate of severe outcomes previously identified in vaccinated healthy individuals as opposed to matched unvaccinated controls, 20 outlining the potential vulnerability of patients with cancer.

Lymphopenia, which has a strong association with severe SARS-CoV-2 infection, 5 was present in 46% of fully vaccinated patients and 28% in the unvaccinated patients. This finding supports the notion that lymphopenic patients with cancer are at high risk for severe disease, even after vaccination. 21 It has been previously shown that lymphocyte-depleted patients such as those receiving anti-CD20 monoclonal antibodies or CAR-T-cell treatment have a much weaker serological response to COVID-19 vaccines. 22 Our results appear to confirm the clinical relevance of such previous observations.

Alternatively, more severe infection with resultant lymphopenia may have been present at diagnosis in vaccinated patients, potentially due to a lower suspicion of SARS-CoV-2 J o u r n a l P r e -p r o o f infection following full vaccination, resulting in a delayed presentation of vaccinated patients with cancer after COVID-19 symptom onset.

Some differences are apparent in the baseline characteristics of the fully vaccinated cohort relative to the unvaccinated population and can partially explain differences in clinical outcomes, even after adjustment. A higher prevalence of active and progressive cancer (19% versus 14%) and of recent receipt of systemic anticancer therapy (56% versus 43%) was seen in the fully vaccinated population relative to unvaccinated patients, with both being previously identified risk factors for adverse COVID-19 outcomes. 5, 10 The number of affected patients in this study is too small to make any definitive conclusions about specific types of anticancer therapy that might be associated with breakthrough infection.

Chronic corticosteroid use (of ≥10 mg/day prednisone dose equivalent), which is associated with higher odds of hospitalization from COVID-19 viral respiratory illness in a cohort of patients with autoimmune conditions, 23 also appeared to be more prevalent at baseline in the fully vaccinated cohort compared to the unvaccinated patients (24% versus 14%).

Following regression analysis, the association between advancing age, active and progressing cancer, ECOG PS of 2 or greater, mCCI of 2 or greater, and lymphopenia with mortality suggests that these established prognostic factors for COVID-19 outcomes remain relevant in defining those patients who may still be at risk of severe outcomes following completion of vaccination.

Limitations of this study include the dependence on clinically annotated data and the reliance on time intervals (instead of exact dates) to capture vaccine administration relative to COVID-19 diagnosis. Given the timeframe of this analysis, it is unlikely that any patients had infection more than 6 months out from vaccination, such that waning immunity is not likely a major factor; future studies will need to consider this as well as receipt of boosters. The true J o u r n a l P r e -p r o o f population prevalence of vaccinated individuals during the time period is unknown and likely changed substantially, as at-risk populations were variably prioritized before vaccines became more generally available in spring 2021. As such, the rate of serious illness or mortality from COVID-19 among the total population of vaccinated patients with cancer is unknown, as vaccination was widely administered and likely protected the majority from serious illness. Strengths include the high-quality data with a robust quality assurance process, along with a comprehensive list of clinical, demographic, and laboratory variables.

With the emergence of the B.1.617.2 (delta) variant, which displays a higher transmissibility than previous strains of the virus, 24 and for which available vaccines appear to show decreased neutralization and efficacy with a higher rate of breakthrough cases, [25] [26] [27] the current findings underscore the need to maintain the implementation of public health measures required to control infection spread and protect vulnerable populations. Delta and subsequent variants will continue to raise the possibility of immune escape from the first generation of vaccines. Additional research is needed to further categorize the patients that remain at risk of symptomatic COVID-19 following vaccination, and test strategies that may reduce this risk. Based on experience in patients with prior organ transplantation, 28 the strategy of administering a third primary series vaccination dose to increase antibody titers is one option recently suggested by the Centres for Disease Control and Prevention to be considered for immunosuppressed patients, including patients with cancer on systemic anticancer therapies (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid- 19-vaccines-us.html) . Further correlation of antibody responses to clinical benefit will be needed to validate the use of these strategies, as well as boosters and emerging strategies such as "mix and match", where a different booster vaccination is administered from the primary vaccination course. 29 J o u r n a l P r e -p r o o f (65) 38 (49) 903 (55) Non-Hispanic White 38 (70) 58 (75) 999 (60) ECOG Performance Status ≥2 9 (17) 14 (18) 224 (14) Modified (23) 339 (20) Cancer status active and progressing 10 (19) 17 (22) 237 (14) Systemic treatment within 3 months 30 (56) 31 (40) 720 (43) Baseline prednisone >10mg/day 9 (17) <5 (<6) 117 (7) ALC ≤1000/µL ( (10) Admitted to intensive care 10 (19) 11 (14) 215 (13) Hospitalized 35 (65) 45 (58) 834 (50) IQR, interquartile range; ALC, absolute lymphocyte count, *numbers add up to <100% as 17 patients were vaccinated but reported as other or unknown type, **numbers are combined as n<5

for one vaccination type, requiring masking per standard CCC19 protocol.

J o u r n a l P r e -p r o o f 

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

Covid-19 and Kidney Transplantation

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Serologic Status and Toxic Effects of the SARS-CoV

BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer

Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic

Seroconversion rates following COVID-19 vaccination among patients with cancer

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer

A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. Cancer Cell

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study

Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Advances

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination

The immuno-oncological challenge of COVID-19. Nat Cancer

Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry

Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Delta Variants of SARS-CoV-2 Cause Significantly Increased Vaccine Breakthrough COVID-19 Cases in

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

Boosting immunity to COVID-19 vaccines

AOR: Multivariable Adjusted Odds Ratio, ref: reference

Vaccination Status: Fully vaccinated (ref = Unvaccinated)

Age (per 10 years increase) Sex: Male (ref = Female)

Cancer status active and progressing: Yes (ref = No)

Modified Charlson Comorbidity Index: 1 (ref = 0)

Modified Charlson Comorbidity Index: >=2 (ref = 0)

ECOG Performance Status: 1 (ref = 0)

ECOG Performance Status: >=2 (ref = 0)

Yes (ref = >=1000/uL) Cancer type: Hematologic (ref = Solid)

log(OR) (95% CI)

Vaccination Status: Fully vaccinated (ref = Unvaccinated)

Age (per 10 years increase) Sex: Male (ref = Female)

Cancer status active and progressing: Yes (ref = No)

Modified Charlson Comorbidity Index: 1 (ref = 0)

Modified Charlson Comorbidity Index: >=2 (ref = 0)

ECOG Performance Status: 1 (ref = 0)

ECOG Performance Status: >=2 (ref = 0)

Yes (ref = >=1000/uL) Cancer type: Hematologic (ref = Solid)

log(OR) (95% CI)

Vaccination Status: Fully vaccinated (ref = Unvaccinated)

Age (per 10 years increase) Sex: Male (ref = Female)

Cancer status active and progressing: Yes (ref = No)

Modified Charlson Comorbidity Index: 1 (ref = 0)

Modified Charlson Comorbidity Index: >=2 (ref = 0)

ECOG Performance Status: 1 (ref = 0)

ECOG Performance Status: >=2 (ref = 0)

Yes (ref = >=1000/uL) Cancer type: Hematologic (ref = Solid)